Kailera Therapeutics, Inc.
- KLRA
- NASDAQ
- Biotechnology
- Obesity/Metabolic Treatments
- Clinical-Stage Biopharma
$11.43
Today +1.60%Quote Oct 19, 2026, 08:00 PM UTC
−10.91%over the last month
Max drawdown −23.8%From 1-month high −12.9%3 months −37.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kailera Therapeutics
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
145
Founded
2024
Market value
$1.48B
Quote Oct 19
Floor
$11.16
2.4% below price
Resistance
$11.74
2.7% above price
Price vs analyst targets
Lowest target
$36.00Highest target
$48.00
$36.00Highest target
$48.00
- Price $11.43
- Average target $42.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 267% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KLRAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free